Medipharm Labs Corp banner

Medipharm Labs Corp
OTC:MEDIF

Watchlist Manager
Medipharm Labs Corp Logo
Medipharm Labs Corp
OTC:MEDIF
Watchlist
Price: 0.0549 USD 2.62%
Market Cap: $22.2m

Wall Street
Price Targets

MEDIF Price Targets Summary
Medipharm Labs Corp

There are no price targets for MEDIF.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Medipharm Labs Corp Competitors:
Price Targets
SPH
Suburban Propane Partners LP
-15% Downside
GFS
Globalfoundries Inc
9% Upside
AMBR
Amber International Holding Ltd
338% Upside

Revenue
Forecast

-20% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
-20% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

For the last 5 years the compound annual growth rate for Medipharm Labs Corp's revenue is -20%. The projected CAGR for the next 2 years is 14%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MEDIF's stock price target?
Not Available

MEDIF doesn't have any price targets made by Wall Street professionals.

What is Medipharm Labs Corp's Revenue forecast?
Projected CAGR
14%

For the last 5 years the compound annual growth rate for Medipharm Labs Corp's revenue is -20%. The projected CAGR for the next 2 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett